Alnylam Pharmaceuticals Inc Stock Ownership - Who owns Alnylam Pharmaceuticals?

Insider buying vs selling

Have Alnylam Pharmaceuticals Inc insiders been buying or selling?
Pushkal GargCMO EVP Dev Med Affairs2023-08-073,112$183.58
Pushkal GargCMO EVP Dev Med Affairs2023-08-07240$185.32
Pushkal GargCMO EVP Dev Med Affairs2023-08-07814$184.65
Yvonne GreenstreetChief Executive Officer2023-08-041,107$186.39
Yvonne GreenstreetChief Executive Officer2023-08-0417$188.40
Yvonne GreenstreetChief Executive Officer2023-08-04192$189.31
Pushkal GargCMO EVP Dev Med Affairs2023-08-0415$188.40
Pushkal GargCMO EVP Dev Med Affairs2023-08-0486$187.37
Pushkal GargCMO EVP Dev Med Affairs2023-08-04945$186.39
Pushkal GargCMO EVP Dev Med Affairs2023-08-041,593$185.54

1 of 9

ALNY insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ALNY insiders and whales buy or sell their stock.

ALNY Shareholders

What type of owners hold Alnylam Pharmaceuticals Inc stock?
Capital World Investors13.17%16,529,308$2.81BInstitution
Ag Novartis11.79%14,800,620$2.52BInsider
Vanguard Group Inc9.29%11,656,831$1.98BInstitution
Fmr LLC8.99%11,281,406$1.92BInstitution
Blackrock Inc6.69%8,393,004$1.43BInstitution
Baillie Gifford Co6.50%8,163,139$1.39BInstitution
Wellington Management Group LLP5.13%6,431,814$1.09BInstitution
Price T Rowe Associates Inc3.13%3,925,004$667.41MInstitution
Dodge Cox2.99%3,747,155$637.17MInstitution

1 of 3

ALNY vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ALNY80.83%19.17%Net Selling
BGNE3.47%34.76%Net SellingNet Selling
BMRN94.07%1.56%Net SellingNet Buying

Alnylam Pharmaceuticals Stock Ownership FAQ

Who owns Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ: ALNY) is owned by 92.64% institutional shareholders, 21.97% Alnylam Pharmaceuticals insiders, and 0.00% retail investors. Ag Novartis is the largest individual Alnylam Pharmaceuticals shareholder, owning 14.80M shares representing 11.79% of the company. Ag Novartis's Alnylam Pharmaceuticals shares are currently valued at $2.52B.

If you're new to stock investing, here's how to buy Alnylam Pharmaceuticals stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.